XV Technology uses patented algorithms adapted from advanced aerodynamics research to process and enhance X-ray and Computed Tomography (CT) images.

4DMedical has commercialized its XV Technology via a Software as a Service (SaaS) model, where patients are scanned using existing imaging equipment and analyzed by 4DMedical remotely.

Founded in 2013, 4DMedical commenced business as 4DX, started as a private company and listed on the Australian Securities Exchange Ltd. (ASX: 4DX) in August 2020.

4DMedical has worked closely with advocacy groups such as Burn Pits 360[4] on difficult-to-diagnose lung diseases in exposed US military veterans.

The XV LVAS report analyzes the lungs in three dimensions (3D) over time, during multiple phases of tidal (normal) breathing, resulting in four-dimensional (4D) measurements.

[8] 4DMedical's wholly owned subsidiary, Australian Lung Health Initiative (ALHI), received AUD$28.9 million in funding from the Australian Federal Government's Medical Research Future Fund (MRFF) Frontier Health and Medical Research[9] to develop the world's first dedicated lung function scanner, XV Scanner.

The Permetium, a small animal scanner, is the first commercially dedicated preclinical imaging system that can quantify regional changes in pulmonary function.